Los Angeles Capital Management LLC Purchases 1,076 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Los Angeles Capital Management LLC boosted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 4.5% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 25,224 shares of the company’s stock after acquiring an additional 1,076 shares during the period. Los Angeles Capital Management LLC’s holdings in Harmony Biosciences were worth $847,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Harmony Biosciences by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 3,684,152 shares of the company’s stock valued at $120,730,000 after acquiring an additional 88,295 shares during the period. Adage Capital Partners GP L.L.C. increased its position in shares of Harmony Biosciences by 18.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,420,000 shares of the company’s stock valued at $46,533,000 after buying an additional 220,000 shares during the period. Pacer Advisors Inc. increased its position in shares of Harmony Biosciences by 534,795.2% during the fourth quarter. Pacer Advisors Inc. now owns 1,224,910 shares of the company’s stock valued at $39,565,000 after buying an additional 1,224,681 shares during the period. Federated Hermes Inc. increased its position in shares of Harmony Biosciences by 2,132.8% during the fourth quarter. Federated Hermes Inc. now owns 525,337 shares of the company’s stock valued at $16,968,000 after buying an additional 501,809 shares during the period. Finally, 683 Capital Management LLC increased its position in shares of Harmony Biosciences by 16.7% during the third quarter. 683 Capital Management LLC now owns 350,000 shares of the company’s stock valued at $11,470,000 after buying an additional 50,000 shares during the period. 86.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

HRMY has been the topic of several analyst reports. Citigroup initiated coverage on Harmony Biosciences in a research report on Friday. They set a “buy” rating and a $48.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $52.00 price target on shares of Harmony Biosciences in a research report on Monday. Mizuho decreased their price target on Harmony Biosciences from $42.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $49.00 price target on shares of Harmony Biosciences in a research report on Friday, April 12th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $41.67.

Harmony Biosciences Stock Down 0.1 %

Shares of HRMY opened at $30.10 on Tuesday. The firm has a market cap of $1.71 billion, a P/E ratio of 13.03, a P/E/G ratio of 0.65 and a beta of 0.72. The stock has a 50 day simple moving average of $29.82 and a two-hundred day simple moving average of $31.27. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.11 and a quick ratio of 3.07. Harmony Biosciences Holdings, Inc. has a 1 year low of $18.61 and a 1 year high of $39.26.

Harmony Biosciences (NASDAQ:HRMY) last issued its earnings results on Tuesday, April 30th. The company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.07. The business had revenue of $154.62 million during the quarter, compared to analyst estimates of $154.10 million. Harmony Biosciences had a return on equity of 28.26% and a net margin of 22.30%. Harmony Biosciences’s revenue for the quarter was up 29.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.48 earnings per share. On average, analysts forecast that Harmony Biosciences Holdings, Inc. will post 1.96 earnings per share for the current fiscal year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.